Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma

WEDNESDAY, Aug. 23, 2023 -- For patients with metastatic melanoma who receive frontline anti-programmed death protein 1 (PD-1) or therapy against programmed cell death 1 ligand 1 and whose tumors progressed with cytotoxic T-lymphocyte protein 4...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news